Zollinger‑Ellison Associated Gastric Bleeding

What is Zollinger‑Ellison associated gastric bleeding?

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) form in the pancreas or duodenum. The excess gastrin stimulates the stomach’s parietal cells to secrete large amounts of gastric acid. When the protective mucus‑bicarbonate layer is overwhelmed, the highly acidic environment erodes the gastric lining, leading to peptic ulcers. If an ulcer erodes into a blood vessel, it can cause gastric bleeding—the hallmark complication of ZES.

In patients with ZES, gastric bleeding may present as:

• Hematemesis (vomiting fresh or coffee‑ground blood)
• Melena (black, tarry stools)
• Occult blood loss leading to anemia

Because the bleeding is driven by uncontrolled acid production, it is often severe, recurrent, and resistant to standard ulcer therapy.

Common Causes

While ZES is the underlying driver, gastric bleeding can also be precipitated by several related conditions. Below are the most frequent contributors:

• 1. Gastrinomas (Zollinger‑Ellison syndrome) – neuroendocrine tumors that secrete gastrin.
• 2. Peptic ulcer disease (PUD) – especially ulcers larger than 2 cm or located on the posterior wall of the duodenum.
• 3. Non‑steroidal anti‑inflammatory drugs (NSAIDs) – inhibit prostaglandin synthesis, weakening the mucosal barrier.
• 4. Helicobacter pylori infection – chronic inflammation increases acid output and ulcer risk.
• 5. Hypertensive gastropathy – portal hypertension can cause mucosal erosion and bleeding.
• 6. Vascular malformations (e.g., Dieulafoy lesion) – abnormal submucosal arteries that can rupture.
• 7. Stress‑related erosive gastritis – severe physiologic stress (trauma, burns, sepsis) can cause diffuse erosions.
• 8. Cancerous lesions (gastric carcinoma, GIST) – malignant tumors may ulcerate and bleed.
• 9. Coagulopathy – liver disease or anticoagulant therapy can exacerbate any mucosal break.
• 10. Medical procedures – endoscopic biopsies or dilation can inadvertently cause bleeding.

Associated Symptoms

Gastric bleeding rarely occurs in isolation. Patients with ZES often experience a cluster of symptoms that reflect both hyperacidity and the systemic effects of chronic blood loss.

• Abdominal pain – usually epigastric, worsening 1–3 hours after meals.
• Diarrhea or steatorrhea – excess acid inactivates pancreatic enzymes.
• Weight loss and malnutrition.
• Heartburn or gastro‑esophageal reflux disease (GERD) refractory to over‑the‑counter meds.
• Fatigue, shortness of breath, or dizziness from anemia.
• Palpitations or rapid heartbeat (tachycardia) when blood loss is significant.
• Fever or chills if bleeding leads to infection (e.g., perforated ulcer).

When to See a Doctor

Because gastric bleeding can become life‑threatening quickly, do not wait for symptoms to resolve on their own. Seek medical attention promptly if you notice any of the following:

• Vomiting bright red blood or material that looks like coffee grounds.
• Black, tarry stools, especially if accompanied by weakness.
• Sudden, severe abdominal pain that does not improve.
• Episodes of fainting, dizziness, or a rapid heartbeat.
• Signs of iron‑deficiency anemia (pale skin, brittle nails, shortness of breath on exertion).
• Persistent heartburn or ulcer pain that does not improve with proton‑pump inhibitors (PPIs).

If you have a known gastrinoma or have been diagnosed with ZES, maintain regular follow‑up and contact your gastroenterology team at the first hint of bleeding.

Diagnosis

Evaluating Zollinger‑Ellison associated gastric bleeding involves a stepwise approach that combines history, laboratory testing, imaging, and endoscopic investigation.

1. Clinical Assessment

The physician will ask detailed questions about:

• Frequency and volume of vomiting blood or melena.
• History of NSAID use, H. pylori infection, or known gastrinoma.
• Weight changes, appetite, and associated abdominal pain.

2. Laboratory Tests

• Complete blood count (CBC) – assesses hemoglobin, hematocrit, and platelet count.
• Serum gastrin level – markedly elevated (>1000 pg/mL) in ZES, especially after a secretin stimulation test.
• Fecal occult blood test (FOBT) – confirms hidden blood loss.
• Electrolytes, BUN/creatinine – help gauge dehydration and renal function.
• Coagulation profile – especially if the patient is on anticoagulants.

3. Imaging Studies

• Contrast‑enhanced CT or MRI – locates gastrinomas in the pancreas, duodenum, or metastatic sites.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – highly sensitive for neuroendocrine tumors.
• Upper abdominal ultrasound – may detect larger lesions but is less sensitive for small gastrinomas.

4. Endoscopy (EGD)

Upper gastrointestinal endoscopy is the gold‑standard for visualizing active bleeding, ulcer location, and severity.

• Identifies bleeding source (active spurting, visible vessel, adherent clot).
• Allows therapeutic interventions (injection, thermal coagulation, clipping, or hemostatic spray).
• Biopsies can be taken to rule out malignancy.

5. Additional Tests

• Secretin stimulation test – confirms gastrinoma when basal gastrin is borderline.
• pH monitoring (24‑hour gastric pH) – documents hyperacidity (pH <2) typical of ZES.

Treatment Options

Management targets two goals: control of acid hypersecretion and hemostasis of the bleeding lesion. A multidisciplinary team (gastroenterology, surgery, endocrinology, interventional radiology) usually coordinates care.

Medical Therapies

• High‑dose Proton‑Pump Inhibitors (PPIs) – e.g., omeprazole 40‑80 mg twice daily or esomeprazole 40 mg twice daily. They reduce gastric acid production >90 % and are first‑line for ZES.
• H2‑Blockers – may be added for breakthrough acid but are less potent than PPIs.
• Octreotide or Lanreotide (somatostatin analogues) – decrease gastrin secretion, shrink gastrinomas, and help control bleeding.
• Antibiotic eradication of H. pylori – clarithromycin‑based triple therapy for 14 days if infection is present.
• Iron supplementation – oral ferrous sulfate or IV iron sucrose for anemia.
• Blood transfusion – packed red cells if hemoglobin <7 g/dL (or higher threshold based on comorbidities).

Endoscopic & Interventional Treatments

• Thermal coagulation (heater probe, bipolar cautery) – seals bleeding vessels.
• Injection therapy – epinephrine or sclerosants to constrict vessels.
• Mechanical clipping – metal clips placed on visible vessels.
• Hemostatic powders (e.g., TC‑325 “Hemospray”) – useful for diffuse oozing.
• Angiographic embolization – interventional radiology can occlude arterial supply when endoscopy fails.

Surgical Options

• Localized gastrinoma resection – enucleation or pancreaticoduodenectomy if the tumor is resectable.
> Pancreaticoduodenectomy (Whipple procedure) – reserved for large or malignant tumors.
• Partial gastrectomy – may be required for refractory ulcer disease or massive bleeding.

Supportive Care & Lifestyle

• Avoid NSAIDs, aspirin, and other ulcerogenic meds.
• Limit alcohol and caffeine, which stimulate acid secretion.
• Eat small, low‑fat meals; avoid eating within 2 hours of bedtime.
• Stay hydrated; replace lost fluids with oral rehydration solutions if mild bleeding.

Prevention Tips

While you cannot control the presence of a gastrinoma, you can reduce the risk of bleeding and ulcer complications.

• Adhere to prescribed high‑dose PPI therapy – never skip doses.
• Regularly monitor serum gastrin and acid levels as advised by your endocrinologist.
• Screen for and eradicate Helicobacter pylori if present.
• Avoid over‑the‑counter NSAIDs, antiplatelet agents, and herbal supplements that irritate the stomach.
• Maintain a balanced diet rich in fruits, vegetables, and lean protein; limit spicy, acidic, and fried foods.
• Quit smoking – tobacco impairs mucus production and promotes ulcer recurrence.
• Schedule routine endoscopic surveillance (usually every 1‑2 years) to detect new ulcers early.
• Stay up‑to‑date with vaccinations (e.g., hepatitis B) if you have a neuroendocrine tumor requiring chemotherapy.

Emergency Warning Signs

**Sources**: Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American College of Gastroenterology, Cleveland Clinic, World Health Organization, Journal of Clinical Endocrinology & Metabolism (2022). Always consult a qualified healthcare professional for personalized advice.